Medtech firm Senseonics' Q2 revenue up 37%, net loss narrows

Reuters
08/07
Medtech firm Senseonics' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue up 37%, net loss narrows

Overview

  • Senseonics Q2 revenue grows 37% yr/yr to $6.6 mln, driven by U.S. patient growth

  • Net loss narrows to $14.5 mln, aided by improved gross profit margins

  • Co raises $77.8 mln to support Eversense 365 launch and pipeline development

Outlook

  • Senseonics expects 2025 revenue of $34-38 mln

  • Company projects 2025 gross margins of 32.5%-37.5%

  • Senseonics anticipates cash use of $60 mln in 2025

  • Revenue expected to be weighted to Q4 due to reorder dynamics

Result Drivers

  • U.S. PATIENT GROWTH - 79% increase in new patient starts in the U.S. drives revenue growth

  • DTC ADVERTISING - Expanded direct-to-consumer campaign boosts leads by 50%

  • GROSS PROFIT MARGINS - Improved margins on 365-day product and one-time tax gain enhance profitability

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

-$0.02

Q2 Net Income

-$14.50 mln

Q2 Gross Profit

$3.12 mln

Q2 Operating Income

-$14.32 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Senseonics Holdings Inc is $1.33, about 61.8% above its August 5 closing price of $0.51

Press Release: ID:nGNX5JVQQ8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10